Drug Discovery Featured Articles & Applications

61. 9 Trends That Will Carry Genomics Into 2020 (And Beyond) 10/24/2016

    Remarkable advances in genomics technologies bring the promise of extraordinary changes in healthcare — and some of those changes are arriving now. What’s unfolding are nine trends that we think will shape the life science markets in this accelerating genomics revolution. First, some background on how we got here.

62. 10 Critical Components Of A Successful Global Drug Development Plan 9/30/2016

    We use plans every day to help us arrive at our desired destinations.  Pilots utilize flight plans prior to take off — although they have flown to their destination perhaps hundreds of times before, they nevertheless reviews and follows a flight plan. Likewise, ship’s captains also file plans and chart courses. Road maps provide guidance on how to drive from point A to point B, though today most people rely on electronic global positioning systems (GPS) to assist with navigation.

63. Opioid Crisis Pushing Changes To U.S. Chronic Pain Drug Market 9/26/2016

    With the U.S opioid analgesic addiction and overdose crisis showing no signs of relenting, change is coming fast for manufacturers of chronic pain drugs.

64. Early Implementation Of Quality By Design For Biological Product Development 8/18/2016

    The idea of thinking in terms of “operational excellence” is a relatively new idea for the biopharmaceutical industry. The enormous uncertainty associated with bringing a biological drug product from discovery to approval almost precludes the thought of forward-thinking in terms of what makes a quality product, especially during early-stage development. However, extensive product knowledge is gathered during early development, and crucial decisions are made in terms moving the science forward to generate the data required to meet your business objectives.

65. CAR T-Cell Therapy: The Road Ahead 8/11/2016

    In recent years, we have witnessed a meteoric rise in clinical studies of cancer immunotherapies, catapulting immuno-oncology into one of the fastest growing and dynamic areas in pharmaceutical development today.

66. Brexit’s Impact On The Global Pharmaceutical Industry: Market Authorization & Pricing 7/12/2016

    The Brexit referendum has resulted in instability and uncertainty for many aspects of British society, including the pharmaceutical industry. As we discussed in Part 1 of this two-part article, life sciences funding and the common market are at risk, and with it billions of dollars in research funding and imports/exports. In this article, we will explore the UK’s future relationship with the EU after exit, which will affect many facets of the worldwide pharmaceutical industry, from marketing authorization to global pricing trends.

67. Brexit’s Impact On The Global Pharmaceutical Industry: Future Access To The EU Common Market 7/6/2016

    On June 23, 2016, the voters of the United Kingdom voted to leave the European Union in an advisory referendum colloquially referred to as the “Brexit” (British exit) vote. The aftermath of the vote has been chaotic — from financial troubles that have seen the British economy and currency plummet, to political bedlam that has led to a number of political casualties, including the Prime Minister and his heir apparent. While analysts, journalists, and the public all discuss the impact of Brexit on the UK and the path forward, few realize the implications that the vote will have on healthcare, and the pharmaceutical industry in particular.

68. QbD: A Framework For Improved Decision Making Throughout Drug Development 3/10/2016

    A frequent complaint of process engineers tasked with implementing quality by design (QbD) is the lack of information provided by their upstream development teams. For QbD to be  implemented efficiently, at least 80% of the knowledge needed for process development must be generated in the R&D phase and transferred downstream.

69. Risks And Challenges Of Having Multiple Products In Your Pipeline 12/22/2015

    As cell therapy companies tackle multiple products in their pipelines and move them from basic research into development and production, the risks and challenges of developing multiple products become clear.

70. Human Biological Samples Sourcing: An Overview 11/12/2015

    Human Biological Samples (HBS) are collected during a biopsy or surgery to diagnose the patient and are preserved for later use by researchers to study the disease progression to bring about potential benefits to the patient community. Despite the varying regulations, HBS collection and biobanking has evolved throughout the years. This whitepaper discusses the trends, supplier landscape, and segmentation by providing visibility to the HBS market and the benefits of engaging with a commercial vs. public biobank.